The FTC settled with Ortho-Clinical Diagnostics, Inc. for misleading consumers about its participation in the EU-U.S. Privacy Shield framework. The company allowed its certification to lapse in 2018 but continued to claim participation. The settlement prohibits such misrepresentations and requires compliance with Privacy Shield obligations for data collected or deletion of such data.
Ortho-Clinical is prohibited from misrepresenting its participation in privacy frameworks, must comply with Privacy Shield obligations for data collected while participating, or return or delete such data.
In-house legal teams should review all agreements involving the transfer of personal data from the European Union to the United States, including vendor contracts, customer agreements, and data processing addendums. Focus on clauses that (1) represent compliance with specific data transfer frameworks like the EU-U.S. Privacy Shield, (2) warrant the accuracy of certification or participation status in such frameworks, (3) outline obligations for data protection, audit rights, and (4) specify data retention, deletion, or return requirements upon termination or lapse of certification. Changes may be needed to ensure representations accurately reflect current certification status, incorporate fallback data transfer mechanisms (e.g., Standard Contractual Clauses), and explicitly require data deletion or return if a framework like Privacy Shield is no longer valid.
Entity
Ortho-Clinical Diagnostics, Inc.
Also known as: Ortho-Clinical Diagnostics
Industry
HealthcareOfficial Press Release
https://www.ftc.gov/news-events/news/press-releases/2020/07/ftc-finalizes-privacy-shield-settlement-ortho-clinical
medical diagnostic device maker settles allegations it misle
https://www.ftc.gov/news-events/news/press-releases/2020/03/medical-diagnostic-device-maker-settles-allegations-it-misled-consumers-about-its-participation-eu
Federal Trade Commission Enforcement Page
https://www.ftc.gov/enforcement
"Ortho-Clinical Diagnostics, Inc."
"The FTC alleged that New Jersey-based Ortho-Clinical Diagnostics, Inc. claimed that it participated in the Privacy Shield framework and complied with the program’s requirements, even though the company had allowed its certification to lapse in 2018."
$750K
The FTC finalized an order against Vanilla Chip LLC (doing business as TruHeight) and its principals for deceptively advertising height-enhancing supplements for children and teens without scientific evidence. The company also used fake reviews and incentivized 5-star ratings. The order requires a $750,000 payment and prohibits false health claims and deceptive review practices.
$2.3M
The FTC alleged that RentGrow, a tenant screening company, violated the Fair Credit Reporting Act (FCRA) by failing to use reasonable procedures to ensure the accuracy of its reports, including by reporting duplicate records and failing to disclose data sources. RentGrow agreed to pay a $2.25 million penalty and is prohibited from further FCRA violations and from misrepresenting dispute outcomes.
The FTC and New York Attorney General took action against Handy Technologies for deceptive earnings claims and failure to disclose fees and fines that led to millions of dollars being withheld from workers' wages. The FTC is sending over $2.7 million in refunds to 62,893 affected consumers.
$35.0M
The FTC alleged that Hopper, a travel booking app, charged consumers hidden and pre-selected fees (Tip and VIP Support) without their consent, misrepresented the benefits of VIP Support and Price Freeze services, and failed to clearly disclose total prices. Hopper agreed to pay $35 million for consumer redress and is prohibited from misrepresenting fees under a proposed order.
$1.5M
The FTC finalized a settlement with Publishing.com LLC and its principals for misleading consumers about potential earnings from self-publishing products. The company will pay $1.5 million and is prohibited from making unsubstantiated earnings claims, failing to disclose refund terms, and misrepresenting endorsements and reviews.
The FTC is seeking public comment on a proposed policy statement addressing concerns that AI companies may be manipulating AI system outputs contrary to consumer expectations for objectivity and accuracy. The statement explains that such conduct could be considered deceptive under Section 5 of the FTC Act. The public comment period runs until July 31, 2026.